Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration

Recombinant human PH20 hyaluronidase (rHuPH20) is used to facilitate dispersion of subcutaneously delivered fluids and drugs. This report summarizes rHuPH20 immunogenicity findings from clinical trials where rHuPH20 was co-administered with SC human immunoglobulin, trastuzumab, rituximab, or insulin...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:AAPS J
Main Authors: Rosengren, Sanna, Dychter, Samuel S., Printz, Marie A., Huang, Lei, Schiff, Richard I., Schwarz, Hans-Peter, McVey, John K., Drake, Fred H., Maneval, Dan C., Kennard, Don A., Frost, Gregory I., Sugarman, Barry J., Muchmore, Douglas B.
Format: Artigo
Jezik:Inglês
Izdano: Springer US 2015
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4540732/
https://ncbi.nlm.nih.gov/pubmed/25967925
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1208/s12248-015-9782-0
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki